Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Trial of AVN-944 in Patients With Advanced Hematologic Malignancies

NCT00273936 is registered in ClinicalTrials.gov with Vertex Pharmaceuticals Incorporated as lead sponsor.

NCT NCT00273936
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00273936 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Trial of AVN-944 in Patients With Advanced Hematologic Malignancies
Lead sponsor
Vertex Pharmaceuticals Incorporated
Phase
Phase 1
Overall status
Completed
Start date
January 31, 2006
Completion date
Not reported
Enrollment
72 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

acute leukemia, chronic leukemia, hodgkin's lymphoma, multiple myeloma, non-hodgkin's lymphoma, waldenstrom's macroglobulinemia